
Scribe Therapeutics to Participate in Upcoming Conferences
|
September 12, 2024
X min read
Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that the Company will participate in the following conferences in September and October:
- Cantor Global Healthcare Conference: Members of management will be participating in the event on Thursday, September 19, 2024 in New York, NY. They will also be available for one-on-one meetings.
- BofA Healthcare Trailblazers Private Company Conference: Members of management will be participating and available for one-on-one meetings on Wednesday, September 25, 2024 in Boston, MA.
- Cell & Gene Meeting on the Mesa: Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present a corporate overview on Wednesday, October 9, 2024 at 10:30 a.m. MST in FLW Ballroom F of the Arizona Biltmore Hotel in Phoenix, AZ. Svetlana Lucas, Ph.D., Chief Business Officer, and David Parrot, Chief Financial Officer, will also be available for one-on-one meetings.
|
September 12, 2024
Share on Social
More like this
News
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
Press
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
May 22, 2025
Read Now
News
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division
May 5, 2025
Read Now
Press
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division
May 5, 2025
Read Now
News
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
April 28, 2025
Read Now
Press
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
April 28, 2025
Read Now